Shares of Profound Medical Corp. (PROF) have gained nearly 14% over the past 1 month and trade around $5.
This commercial-stage medical device company focuses on the development and marketing of customizable, incision-free therapeutic systems for the ablation of diseased tissue. Its lead product is the FDA-cleared TULSA-PRO system, a minimally invasive, AI-powered, MRI-guided, and robotically driven solution for prostate disease, which is covered by Medicare. The device is FDA-cleared, CE Marked and also approved in Canada.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.